Additionally, CD8+ T cells themselves are more susceptible to ferroptosis compared to the tumor cells, which may restrict the therapeutic efficacy of ferroptosis inducers in cancer treatment (Li et al., 2024; Lin et al., 2024). This evidence concerns the gene CD8A and neoplasm.